Source comparison
Receptor Mechanism: GHRH Pathway vs Ghrelin Pathway
CJC-1295 no DAC and Sermorelin both bind to the GHRH receptor (GHRHR) on anterior pituitary somatotroph cells, triggering cAMP-mediated signalling that increases intracellular calcium and drives GH synthesis and secretion. The 'no DAC' designation refers to th
This comparison does not assign a generated winner or score.
- CJC-1295 no DAC and Sermorelin both bind to the GHRH receptor (GHRHR) on anterior pituitary somatotroph cells, triggering cAMP-mediated signalling that increases intracellular calcium and drives GH synthesis and secretion. The 'no DAC' designation refers to the absence of Drug Affinity Complex modification. CJC-1295 with DAC has an added lysine linkage that extends half-life to 6–8 days but also blunts the natural pulsatile rhythm that defines healthy GH secretion. Without DAC, CJC-1295 retains a 6–8 hour half-life that allows it to amplify naturally occurring GH pulses (which peak during deep sleep and post-exercise) rather than creating sustained elevation.
- Ipamorelin operates through the ghrelin receptor, also called growth hormone secretagogue receptor type 1a (GHSR-1a). This receptor sits on the same somatotroph cells but activates a distinct signalling pathway. Specifically phospholipase C and protein kinase C cascades. What makes Ipamorelin unique among ghrelin mimetics is its high selectivity: it stimulates GH release without co-activating ACTH (which drives cortisol) or prolactin pathways that GHRP-2 and GHRP-6 trigger. A study published in the Journal of Clinical Endocrinology & Metabolism confirmed Ipamorelin produced zero statistically significant cortisol or prolactin elevation across dosing ranges from 0.5–2.0 mcg/kg in human subjects.
- Sermorelin, as a direct GHRH(1-29) fragment, mirrors the exact sequence your hypothalamus produces naturally. Its advantage: it cannot override the body's negative feedback loop controlled by somatostatin (the hormone that suppresses GH release between pulses). This makes Sermorelin physiologically 'safe' in the sense that it amplifies existing pulses rather than forcing secretion when somatostatin levels are high. The trade-off: its 10–20 minute half-life means therapeutic windows are narrow. Most protocols dose Sermorelin subcutaneously 30–60 minutes before bed to coincide with the largest natural GH surge.